76,512 results match your criteria Secondary Lung Tumors


Development and comparison of novel bioluminescent mouse models of pancreatic neuroendocrine neoplasm metastasis.

Sci Rep 2021 May 13;11(1):10252. Epub 2021 May 13.

Department of Neuroscience and Pharmacology, University of Iowa, 2-570 Bowen Science Building, 51 Newton Road, Iowa City, IA, 52242, USA.

Pancreatic neuroendocrine neoplasms (pNENs) are slow growing cancers of increasing incidence that lack effective treatments once they become metastatic. Unfortunately, nearly half of pNEN patients present with metastatic liver tumors at diagnosis and current therapies fail to improve overall survival. Pre-clinical models of pNEN metastasis are needed to advance our understanding of the mechanisms driving the metastatic process and for the development of novel, targeted therapeutic interventions. Read More

View Article and Full-Text PDF

Higher mortality in lung cancer patients with COVID-19? A systematic review and meta-analysis.

Lung Cancer 2021 May 5. Epub 2021 May 5.

Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital, Chongqing, 400030, China. Electronic address:

Objective: Given that the coronavirus disease 2019 (COVID-19) mainly spreads through the respiratory system and is associated with severe pulmonary complications, lung cancer patients may have worse outcomes than those with other tumors. There is no confirmed evidence about the mortality comparison between COVID-19 patients with lung cancer and other tumors. We performed a systematic review and pooled analysis to provide precise estimates of the mortality rate of COVID-19 patients with lung cancer and other tumors. Read More

View Article and Full-Text PDF

Metastatic Hepatic Epitheloid Hemangioendothelioma in a Young Male: A Rare Presentation.

Gastrointest Tumors 2021 Apr 18;8(2):58-62. Epub 2021 Feb 18.

Department of General Surgery, AIIMS, Bhopal, Madhya Pradesh, India.

Hepatic EHE (epithelioid hemangioendothelioma) is an uncommon entity of vascular origin and a low-grade malignant tumor. Primary hepatic EHE is rare. These tumors can be multifocal at presentation like in the soft tissues, bones, brain, liver, and small intestine. Read More

View Article and Full-Text PDF

Paraneoplastic optic neuropathy secondary to adenocarcinoma of the lung.

BMJ Case Rep 2021 May 12;14(5). Epub 2021 May 12.

Department of Ophthalmology, University of Science Malaysia-Kesihatan Campus, Kubang Kerian, Kelantan, Malaysia.

We describe an uncommon cause of paraneoplastic optic neuropathy in adenocarcinoma of the lung. A 45-year-old healthy woman presented with seizure and encephalitis, followed by an acute visual loss in both eyes for 1 week. Her visual acuity was no perception of light in the right eye and hand movement in the left eye. Read More

View Article and Full-Text PDF

[A Long‒Term Survival Case of Advanced Rectal Cancer with Liver and Lung, Para‒Aortic Lymph Nodes Metastasis That Responded to Multidisciplinary Therapy].

Gan To Kagaku Ryoho 2021 Apr;48(4):566-568

Dept. of Surgery, Yokohama City University.

The patient was a 59‒year‒old woman. In 2005, she underwent low anterior resection plus D2 dissection for rectal cancer (pT4aN2aM0, pStage Ⅲb). In 2007, she underwent hepatic S8 subsegment resection for liver metastasis. Read More

View Article and Full-Text PDF

[Change in Therapy for Malignant Pleural Mesothelioma at Our Hospital].

Gan To Kagaku Ryoho 2021 Apr;48(4):513-517

Dept. of Surgery, Okayama Rosai Hospital.

When molecular target drug began to be used for chemotherapy to treat malignant pleural mesothelioma in 2014, we introduced this treatment strategy for 61 patients who were diagnosed and were being treated in our hospital. Chemotherapy was performed on 37 patients, while 12 patients underwent surgical remedy and best supportive care was provided to another 12 patients. Molecular target drug was used as the primary chemotherapy treatment in 14 cases, while it was the secondary treatment in 22 others. Read More

View Article and Full-Text PDF

A case report of right upper lung adenosquamous carcinoma resection following neoadjuvant targeted therapy.

Ann Palliat Med 2021 Apr;10(4):4987-4993

Department of Thoracic Surgery, Fuzhou Pulmonary Hospital of Fujian, Fuzhou, China.

The patient was a middle-aged male smoker who had space-occupying lesions in the right upper lung, Positron emission tomography-computed tomography (PET-CT) suggested right upper lung cancer with multiple mediastinal lymph node metastases. Endobronchial ultrasound-guided transbronchial lung biopsy (EBUS-GS-TBLB) performed in the bronchus of the right apical segment confirmed the lesion as squamous cell carcinoma. Neoadjuvant therapy was planned. Read More

View Article and Full-Text PDF

Benefits of Continuous Positive Airway Pressure (CPAP) During Radiation Therapy: A Prospective Trial.

Int J Radiat Oncol Biol Phys 2021 May 5. Epub 2021 May 5.

Department of Radiation Oncology, Chaim Sheba Medical Center, Tel Hashomer, Israel; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel. Electronic address:

Purpose: This study aimed to study the impact of continuous positive airway pressure (CPAP) on chest anatomy and tumor motion in patients receiving radiation therapy.

Methods And Materials: Patients with primary or secondary lung tumors, left-sided breast cancer, or liver metastases referred for radiation therapy were trained to breathe with a CPAP device using a face mask to a maximal pressure of 15 cm HO. Three- and 4-dimensional computed tomography simulation was performed twice for each patient: once with free breathing (FB) and again using CPAP. Read More

View Article and Full-Text PDF

Checkpoint inhibition in combination with an immunoboost of external beam radiotherapy in solid tumors (CHEERS): study protocol for a phase 2, open-label, randomized controlled trial.

BMC Cancer 2021 May 7;21(1):514. Epub 2021 May 7.

Cancer Research Institute Ghent (CRIG), Ghent University, Ghent, Belgium.

Background: While the introduction of checkpoint inhibitors (CPIs) as standard of care treatment for various tumor types has led to considerable improvements in clinical outcome, the majority of patients still fail to respond. Preclinical data suggest that stereotactic body radiotherapy (SBRT) could work synergistically with CPIs by acting as an in situ cancer vaccine, thus potentially increasing response rates and prolonging disease control. Though SBRT administered concurrently with CPIs has been shown to be safe, evidence of its efficacy from large randomized trials is still lacking. Read More

View Article and Full-Text PDF

An unusual case of aggressive malignant spread of epithelioid hemangioendothelioma.

Rare Tumors 2021 20;13:20363613211010858. Epub 2021 Apr 20.

Department of Oncology, Mayo Clinic, Rochester, MN, USA.

Epithelioid hemangioendothelioma (EHE) is a rare vascular neoplasm which typically originates from liver, lung, or bone. Due to the low incidence of disease, the most effective treatment is not easily studied and much of the information known about EHE has been learned through case reports and case series. In this case, we will present an uncommon form of primary soft tissue EHE with local recurrence, bone metastasis, and lymphangitic spread to the lungs leading to respiratory failure. Read More

View Article and Full-Text PDF

The ratio of T790M to EGFR-activating mutation predicts response of osimertinib in 1st or 2nd generation EGFR-TKI-refractory NSCLC.

Sci Rep 2021 May 5;11(1):9629. Epub 2021 May 5.

Department of Thoracic Malignancy, Osaka Habikino Medical Center, Habikino 3-7-1, Habikino City, Osaka, 583-8588, Japan.

The most frequent mechanism of resistance after 1st/2nd-generation (G) epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) is secondary point mutation Thr790Met (T790M) in EGFR. Afatinib followed by osimertinib (Afa group) may provide better outcomes for T790M-positive non-small cell lung cancer (NSCLC) than 1st-G EGFR-TKI followed by osimertinib (1st-G group). We studied 111 consecutive NSCLC patients with T790M mutation treated with osimertinib after progression following 1st/2nd-G EGFR-TKI between March 28, 2016 and March 31, 2018. Read More

View Article and Full-Text PDF

Comparison of Chemotherapeutic Regimens Frequently Used in Metastatic Non-squamous NSCLC Treatment.

Anticancer Res 2021 May;41(5):2597-2603

Department of Pneumology and Phthisiology, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic

Background/aim: Platinum-based chemotherapy with pemetrexed or paclitaxel/bevacizumab are regimens used in combination with checkpoint inhibitors in non-squamous non-small cell lung cancer (NSCLC) treatment. We conducted a real-world study to compare the outcomes of these chemotherapeutic regimens.

Patients And Methods: We investigated 1,534 patients with advanced non-squamous NSCLC treated with platin/pemetrexed (n=1212) or platin/paclitaxel/bevacizumab (n=322) in 9 cancer centres in the Czech Republic. Read More

View Article and Full-Text PDF

Effective Control of Brain Metastases Irrespective of Distance from Isocenter in Single-isocenter Multitarget Stereotactic Radiosurgery.

Anticancer Res 2021 May;41(5):2575-2581

Department of Radiology, Shiga University of Medical Science, Otsu, Japan.

Background/aim: Few previous studies have evaluated the effectiveness of single-isocenter multitarget (SIMT) stereotactic radiosurgery (SRS) in clinical practice.

Patients And Methods: Gross tumor volumes of 113 metastases in 13 patients were measured by contrast-enhanced magnetic resonance imaging. Prescribed doses were set at 20-24 Gy. Read More

View Article and Full-Text PDF

What Is the Clinical Impact of Sending Tissue for Histopathology During Surgery for Known, Diffuse Metastatic Disease to Bone?

Anticancer Res 2021 May;41(5):2473-2476

Department of Orthopedic Surgery, Section of Orthopedic Oncology, Rush University Medical Center, Chicago, IL, U.S.A.

Background/aim: During surgery for patients with known, diffuse metastatic bone disease (MBD), lesional tissue is routinely sent for pathological evaluation. However, there are limited data to assess whether there is a role for histopathology for MBD despite time and cost of interpretation, as well as whether a positive sample changes the subsequent treatment course.

Patients And Methods: Sixty-six cases from 2017 to 2020 were reviewed retrospectively. Read More

View Article and Full-Text PDF

Significance of pulmonary resection in patients with metachronous pulmonary metastasis from pancreatic ductal adenocarcinoma: a retrospective cohort study.

BMC Surg 2021 May 5;21(1):237. Epub 2021 May 5.

Department of Gastroenterological Surgery, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa, 259-1193, Japan.

Background: Pulmonary metastases from pancreatic ductal adenocarcinoma (PDAC) are relatively rare. Systemic chemotherapy is the first choice of treatment in patients with distant metastases, and the role of metastasectomy is controversial. The aim of the present study was to evaluate the outcome of patients with pulmonary metastases after resection of PDAC and the indications for metastasectomy. Read More

View Article and Full-Text PDF

Sarcomatoid carcinoma associated with chronic empyema and early lung and pleural metastases: A case report.

Medicine (Baltimore) 2021 May;100(18):e25692

Department of Pathology, Inha University Hospital, Inha University College of Medicine, Jung-gu, Incheon, South Korea.

Introduction: The relationship between chronic empyema and malignant tumors, most of which are lymphoma, has been recognized for many decades. Sarcomatoid carcinoma associated with chronic empyema is extremely rare, may metastasize to other organs in the early stage, and rapidly progresses to death. As far as we know, this was the first case report on sarcomatoid carcinoma associated chronic empyema. Read More

View Article and Full-Text PDF

Comprehensive TCM treatments combined with chemotherapy for advanced non-small cell lung cancer: A randomized, controlled trial.

Medicine (Baltimore) 2021 May;100(18):e25690

Oncology Center, The First Affiliated Hospital of Guangzhou University of Chinese Medicine.

Objective: We conducted this study to evaluate the efficacy and safety of traditional Chinese medicine (TCM) in advanced non-small cell lung cancer (NSCLC) patients who underwent chemotherapy.

Design: This was a prospective, open-label, randomized controlled trial. NSCLC patients at stage IIIA, IIIB, or IV were randomly assigned to either TCM plus chemotherapy or chemotherapy alone. Read More

View Article and Full-Text PDF

Complete remission of advanced low-grade endometrial stromal sarcoma after aromatase inhibitor therapy: a case report.

J Med Case Rep 2021 May 5;15(1):262. Epub 2021 May 5.

Intern, King Abdullah University Hospital, Jordan University of Science & Technology, Irbid, 22110, Jordan.

Background: Low-grade endometrial stromal sarcoma is a rare neoplastic growth in the uterine cavity, representing less than 1% of uterine tumors. Such tumors usually affect premenopausal and perimenopausal women, with a mean age of 46 years. Treatment generally starts with surgical resection of the tumor, followed by chemotherapy, radiotherapy, or hormonal therapy. Read More

View Article and Full-Text PDF

Host-dependent Phenotypic Resistance to EGFR Tyrosine Kinase Inhibitors.

Cancer Res 2021 May 3. Epub 2021 May 3.

Biological Regulation, Weizmann Institute of Science

Lung cancers driven by mutant forms of the epidermal growth factor receptor (EGFR) invariably develop resistance to kinase inhibitors, often due to secondary mutations. Here we describe an unconventional mechanism of resistance to dacomitinib, a newly approved covalent EGFR kinase inhibitor, and uncover a previously unknown step of resistance acquisition. Dacomitinib-resistant derivatives of lung cancer cells were established by means of gradually increasing dacomitinib concentrations. Read More

View Article and Full-Text PDF

A novel mutation in gene in a patient with Carney complex presenting with pituitary macroadenoma, acromegaly, Cushing's syndrome and recurrent atrial myxoma.

Arch Endocrinol Metab 2021 Apr 29. Epub 2021 Apr 29.

Endocrinologist, Practicing at Private Practice, Karaj, Iran.

Carney complex (CNC) is a rare syndrome of multiple endocrine and non-endocrine tumors. In this paper we present a 23-year-old Iranian woman with CNC who harbored a novel mutation (c.642dupT) in gene. Read More

View Article and Full-Text PDF

Solitary pancreatic metastasis of occult pulmonary small cell carcinoma diagnosed by EUS-FNA cytology: a case report.

Int J Clin Exp Pathol 2021 15;14(4):514-518. Epub 2021 Apr 15.

Department of Gastroenterology and Hepatology, Shiga General Hospital Japan.

A 74-year-old man presented with symptoms suggestive of acute pancreatitis, and a mass lesion measuring 25 mm was detected in the pancreatic head. Cytological and histopathological examinations of EUS-FNA specimens taken from the lesion demonstrated small cell (neuroendocrine) carcinoma. Tumor cells were immunoreactive for cytokeratin, synaptophysin, chromogranin A, CD56, and TTF-1, and PET-CT of the chest revealed a small tumor in the upper lobe of the left lung. Read More

View Article and Full-Text PDF

The relationship among primary anatomic subsite and risk and distribution of second malignant neoplasms in patients with stage I/II diffuse large B-cell lymphoma: An analysis of the surveillance, epidemiology, and end results database.

Transl Oncol 2021 Apr 28;14(7):101106. Epub 2021 Apr 28.

Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; Collaborative Innovation Center of Hematology, Huazhong University of Science and Technology, Wuhan, China.

Background: Recent studies have reported that diffuse large B-cell lymphoma (DLBCL) involving different primary extranodal sites have distinct clinicopathological characteristics and prognosis. However, the risk of secondary malignant neoplasms (SMNs) in DLBCL survivors with different primary extranodal sites are unknown.

Methods: A total of 40,714 patients diagnosed with stage I/II DLBCL were included from the Surveillance, Epidemiology, and End Results (SEER) database from 1983 to 2015. Read More

View Article and Full-Text PDF

Binding of tyrosine kinase inhibitor to epidermal growth factor receptor: surface-enhanced infrared absorption microscopy reveals subtle protein secondary structure variations.

Nanoscale 2021 Apr;13(16):7667-7677

Elettra Sincrotrone Trieste SCpA, S.S. 14 Km 163.5, I-34149, Basovizza, Trieste, Italy.

Surface-Enhanced Infrared Absorption (SEIRA) has been proposed as a valuable tool for protein binding studies, but its performances have been often proven on model proteins undergoing severe secondary structure rearrangements, while ligand binding only marginally involves the protein backbone in the vast majority of the biologically relevant cases. In this study we demonstrate the potential of SEIRA microscopy for highlighting the very subtle secondary structure modifications associated with the binding of Lapatinib, a tyrosine kinase inhibitor (TKI), to epidermal growth factor receptor (EGFR), a well-known driver of tumorigenesis in pathological settings such as lung, breast and brain cancers. By boosting the performances of Mid-IR plasmonic devices based on nanoantennas cross-geometry, accustoming the protein purification protocols, carefully tuning the protein anchoring methodology and optimizing the data analysis, we were able to detect EGFR secondary structure modification associated with few amino acids. Read More

View Article and Full-Text PDF

Ocular Oncology-Primary and Metastatic Malignancies.

Med Clin North Am 2021 May 2;105(3):531-550. Epub 2021 Apr 2.

Medicine, 231 Albert Sabin Way, Suite 5412, Cincinnati, OH 45267-0567, USA. Electronic address: https://twitter.com/mauradinicola.

Several neoplastic processes can involve the eye, either primarily or secondary to a systemic malignancy. The most common primary tumors of the eye include conjunctival and uveal melanoma, retinoblastoma, conjunctival and intraocular lymphoma, and ocular surface squamous neoplasia. Metastatic spread from systemic malignancies, especially of the breast and lung, also can involve the eye. Read More

View Article and Full-Text PDF

Long Non-Coding RNA CRNDE Is Involved in Resistance to EGFR Tyrosine Kinase Inhibitor in EGFR-Mutant Lung Cancer via eIF4A3/MUC1/EGFR Signaling.

Int J Mol Sci 2021 Apr 13;22(8). Epub 2021 Apr 13.

Division of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Bunkyo-ku, Tokyo 113-8602, Japan.

(1) Background: Acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) is an intractable problem for many clinical oncologists. The mechanisms of resistance to EGFR-TKIs are complex. Long non-coding RNAs (lncRNAs) may play an important role in cancer development and metastasis. Read More

View Article and Full-Text PDF

Hypoxia-Induced Regulates the Proliferation and Metastasis of Non-Small Cell Lung Cancer Cells.

Int J Mol Sci 2021 Apr 21;22(9). Epub 2021 Apr 21.

Institute of Human Genetics, Polish Academy of Sciences, Strzeszyńska 32, 60-479 Poznań, Poland.

Hypoxia in non-small cell lung cancer (NSCLC) affects cancer progression, metastasis and metabolism. We previously showed that FAM13A was induced by hypoxia in NSCLC but the biological function of this gene has not been fully elucidated. This study aimed to investigate the role of hypoxia-induced FAM13A in NSCLC progression and metastasis. Read More

View Article and Full-Text PDF

[Detection of circulating tumor cells with chromosomes 7 and 8 polysomy in non-small cell lung cancer and its correlation with epidermal growth factor receptor mutations in cancer tissue].

Zhonghua Bing Li Xue Za Zhi 2021 May;50(5):447-452

Department of Pathology, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, China.

To investigate the value of chromosomes 7 and 8 polysomy in circulating tumor cells (CTCs) for the diagnosis of non-small cell lung cancer, and the correlation of CTCs with clinical pathological characteristics and epidermal growth factor receptor (EGFR) mutations in cancer tissue. Fifty-seven patients with non-small cell lung cancer and 21 patients with benign lung diseases were enrolled at Beijing Chaoyang Hospital, Capital Medical University, Beijing, China from November 2017 to October 2020. Negative enrichment combined with immunofluorescence in situ hybridization (imFISH) was used to identify CTCs polysomy on chromosomes 7 and 8. Read More

View Article and Full-Text PDF

Benign Metastasizing Leiomyoma in the Heart of a 45-Year-Old Woman.

Tex Heart Inst J 2021 Jan;48(1)

Harrington Heart & Vascular Institute, Cardiovascular Medicine Department, University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine, Cleveland, Ohio.

We report a rare case of benign metastasizing leiomyoma in the heart of a 45-year-old woman 2 years after a uterine leiomyoma had been discovered during hysterectomy. Computed tomograms at presentation showed a large mixed cystic mass in the pelvis and bilateral lung nodules suggestive of metastatic disease. A large cardiac mass, attached to the chordae of the tricuspid valve and later shown to be histopathologically consistent with uterine leiomyoma, was successfully resected through a right atriotomy. Read More

View Article and Full-Text PDF
January 2021

Long-term prognosis of patients with resected adenocarcinoma in situ and minimally invasive adenocarcinoma of the lung.

J Thorac Oncol 2021 Apr 26. Epub 2021 Apr 26.

Department of Thoracic Surgery, National Cancer Center Hospital, 5-1-1, Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.

Introduction: The WHO classification of lung tumors defines adenocarcinoma in situ (AIS) and minimally invasive adenocarcinoma (MIA) as cancers with no or limited histological invasive components. The probability of patients with AIS or MIA being recurrence-free for 5 years postoperatively has been shown to be 100%. This study aimed to analyze the prognosis of patients with AIS or MIA after more than 5 postoperative years. Read More

View Article and Full-Text PDF

Risk of cardiovascular mortality with androgen deprivation therapy in prostate cancer: A secondary analysis of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Randomized Controlled Trial.

Cancer 2021 Apr 27. Epub 2021 Apr 27.

Department of Radiation Oncology, Dana-Farber Cancer Institute/Brigham and Women's Hospital, Boston, Massachusetts.

Background: For men with radiation-managed prostate cancer, there is conflicting evidence regarding the association between androgen deprivation therapy (ADT) and cardiovascular mortality (CVM), particularly among those who have with preexisting comorbidities. The objective of this study was to analyze the association between ADT and CVM across patient comorbidity status using prospectively collected data from a large clinical trial.

Methods: In total, 1463 men were identified who were diagnosed with clinically localized, intermediate-risk/high-risk prostate cancer (T2b-T4, Gleason 7-10, or prostate-specific antigen >10 ng/mL) from 1993 to 2001 and managed with either radiation therapy (RT) alone or RT plus ADT during the randomized Prostate, Lung, Colon, and Ovarian (PLCO) Cancer Screening Trial. Read More

View Article and Full-Text PDF